United States · Investor

BioMed Ventures

Last cheque observed Nov 2015. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietGrowth equity

Series CSeries BSeries DSoftwareWeb Development

Cheques on record
0%of best year0cheques in 12 months, 14 on record
Since the last cheque4002days00hrs00min00sec
Median round$33MRounds led0 of 14Exits2 from the portfolioMostly inUnited States, 100%
Pitch BioMed Ventures

BioMed Ventures highlights

  1. 01

    14 rounds on record

  2. 02

    Mostly Series C and Series B: 57% of its rounds

  3. 03

    2 exits from the portfolio

What they do

Type
Growth equity (from a list, unverified)
Cheque size
Not stated
Sectors
SoftwareWeb Development
Based in
United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first14 appearances

  1. 2015

    6 rounds

  2. Nov
    Amplyx PharmaceuticalsSeries B · US$41MWith 2 others
  3. Aug
    Syndax PharmaceuticalsSeries C · US$80MWith 12 others
  4. Jul
    AnaptysBioSeries D · US$40MWith 4 others
  5. May
    AEGEA MedicalSeries C · US$36MWith 5 others
  6. Apr
    Edge TherapeuticsSeries C · US$56MWith 5 others
  7. Feb
    Laguna PharmaceuticalsSeries B · US$30MWith 3 others
  8. 2014

    2 rounds

  9. Sept
    TRACON PharmaceuticalsSeries B · US$27MWith 5 others
  10. Jan
    Auspex PharmaceuticalsSeries E · US · sec.gov$20MWith 4 others
  11. 2013

    1 round

  12. Sept
    Zosano PharmaDebt · US$3.0MWith 2 others
  13. 2012

    3 rounds

  14. Dec
    NanoString TechnologiesSeries E · US · reuters.com$15MWith 6 others
  15. Jul
    HistogenicsSeries C · US$49MWith 2 others
  16. Jul
    HistogenicsSeries A · US · masshightech.com$49MWith 2 others
  17. 2011

    1 round

  18. Nov
    NanoString TechnologiesSeries D · US · xconomy.com$20MWith 5 others
  19. 2008

    1 round

  20. Jan
    AmpliMed CorporationSeries C · US$5.0MWith 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Exits from the portfolio

Companies it backed that were later bought or listed2 in all

Auspex PharmaceuticalsBought by Teva Pharmaceutical Industries$3.2BMar 2015
NanoString TechnologiesListed$54MJun 2013

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as BioMed Ventures. A count of rooms they were both in, not a relationship either has claimed.

New Enterprise AssociatesVC firm3rounds togetherSofinnova InvestmentsVC firm3rounds togetherClarus VenturesVC firm2rounds togetherCormorant Asset ManagementPrivate equity2rounds togetherDFJVC firm2rounds togetherFrazier Healthcare PartnersPrivate equity2rounds togetherOVP Venture PartnersVC firm2rounds togetherSplit Rock PartnersVC firm2rounds together

Quick answers about BioMed Ventures

What does BioMed Ventures invest in?

BioMed Ventures invests most often at Series C and Series B (57% of the rounds on record), in sectors such as Software and Web Development.

How active is BioMed Ventures?

14 investments on record, 0 of them in the last 12 months. The most recent was in Nov 2015.

How big are BioMed Ventures's cheques?

The median round it joins is $33M.

Does BioMed Ventures lead rounds?

Rarely, if at all: none of its 14 investments on record names it as the lead.

Where does BioMed Ventures invest?

Most of the companies it backs are in the United States (100%).

Is BioMed Ventures investing now?

No investments in the last 12 months; the latest was in Nov 2015.

Who does BioMed Ventures invest alongside?

Most often New Enterprise Associates (3 rounds together), Sofinnova Investments (3 rounds together) and Clarus Ventures (2 rounds together).

What kind of investor is BioMed Ventures?

BioMed Ventures is a growth equity firm based in United States.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it